-
1دورية أكاديمية
المؤلفون: Plaisy, Marie Kerbie, Minga, Albert K, Wandeler, Gilles, Murenzi, Gad, Samala, Niharika, Ross, Jeremy, Lopez, Alvaro, Mensah, Ephrem, de Waal, Renée, Kuniholm, Mark H, Diero, Lameck, Salvi, Sonali, Moreira, Rodrigo, Attia, Alain, Mandiriri, Ardele, Shumbusho, Fabienne, Goodrich, Suzanne, Rupasinghe, Dhanushi, Alarcon, Paola, Maruri, Fernanda, Perrazo, Hugo, Jaquet, Antoine
المصدر: Plaisy, Marie Kerbie; Minga, Albert K; Wandeler, Gilles; Murenzi, Gad; Samala, Niharika; Ross, Jeremy; Lopez, Alvaro; Mensah, Ephrem; de Waal, Renée; Kuniholm, Mark H; Diero, Lameck; Salvi, Sonali; Moreira, Rodrigo; Attia, Alain; Mandiriri, Ardele; Shumbusho, Fabienne; Goodrich, Suzanne; Rupasinghe, Dhanushi; Alarcon, Paola; Maruri, Fernanda; . (2024). Metabolic causes of liver disease among adults living with HIV from low- and middle-income countries: a cross-sectional study. Journal of the International AIDS Society, 27(4) BioMed Central 10.1002/jia2.26238
مصطلحات موضوعية: 610 Medicine & health
الوصف: INTRODUCTION Liver disease is a leading cause of morbidity and mortality among persons living with HIV (PLHIV). While chronic viral hepatitis has been extensively studied in low- and middle-income countries (LMICs), there is limited information about the burden of metabolic disorders on liver disease in PLHIV. METHODS We conducted a cross-sectional analysis of baseline data collected between October 2020 and July 2022 from the IeDEA-Sentinel Research Network, a prospective cohort enrolling PLHIV ≥40 years on antiretroviral treatment (ART) for ≥6 months from eight clinics in Asia, Americas, and central, East, southern and West Africa. Clinical assessments, laboratory testing on fasting blood samples and liver stiffness measurement (LSM)/controlled attenuation parameter (CAP) by vibration-controlled transient elastography were performed. Multivariable logistic regression models assessed factors associated with liver fibrosis (LSM ≥7.1 kPa) and steatosis (CAP ≥248 dB/m). Population attributable fraction (PAF) of each variable associated with significant liver fibrosis was estimated using Levin's formula. RESULTS Overall, 2120 PLHIV (56% female, median age 50 [interquartile range: 45-56] years) were included. The prevalence of obesity was 19%, 12% had type 2 diabetes mellitus (T2DM), 29% had hypertension and 53% had dyslipidaemia. The overall prevalence of liver fibrosis and steatosis was 7.6% (95% confidence interval [CI] 6.1-8.4) and 28.4% (95% CI 26.5-30.7), respectively, with regional variability. Male sex at birth (odds ratio [OR] 1.62, CI 1.10-2.40), overweight/obesity (OR = 2.50, 95% CI 1.69-3.75), T2DM (OR 2.26, 95% CI 1.46-3.47) and prolonged exposure to didanosine (OR 3.13, 95% CI 1.46-6.49) were associated with liver fibrosis. Overweight/obesity and T2DM accounted for 42% and 11% of the PAF for liver fibrosis, while HBsAg and anti-HCV accounted for 3% and 1%, respectively. Factors associated with steatosis included overweight/obesity (OR 4.25, 95% CI 3.29-5.51), T2DM (OR 2.06, 95% CI 1.47-2.88), prolonged ...
وصف الملف: application/pdf
العلاقة: https://boris.unibe.ch/195638Test/
-
2دورية أكاديمية
المؤلفون: JOHNSON, Leigh F., KARIMINIA, Azar, TRICKEY, Adam, YIANNOUTSOS, Constantin T., EKOUEVI, Didier Koumavi, MINGA, Albert K., PASCOM, Ana Roberta Pati, HAN, Win Min, ZHANG, Lei, ALTHOFF, Keri N., REBEIRO, Peter F., MURENZI, Gad, ROSS, Jonathan, HSIAO, Nei Yuan, MARSH, Kimberly
مصطلحات موضوعية: Antiretroviral therapy, HIV, Viral load, Sciences du Vivant [q-bio]/Santé publique et épidémiologie
الوصف: INTRODUCTION: The third of the Joint United Nations Programme on HIV/AIDS (UNAIDS) 90-90-90 targets is to achieve a 90% rate of viral suppression (HIV viral load <1000 HIV-1 RNA copies/ml) in patients on antiretroviral treatment (ART) by 2020. However, some countries use different thresholds when reporting viral suppression, and there is thus a need for an adjustment to standardize estimates to the <1000 threshold. We aim to propose such an adjustment, to support consistent monitoring of progress towards the "third 90" target. METHODS: We considered three possible distributions for viral loads in ART patients: Weibull, Pareto and reverse Weibull (imposing an upper limit but no lower limit on the log scale). The models were fitted to data on viral load distributions in ART patients in the International epidemiology Databases to Evaluate AIDS (IeDEA) collaboration (representing seven global regions) and the ART Cohort Collaboration (representing Europe), using separate random effects models for adults and children. The models were validated using data from the World Health Organization (WHO) HIV drug resistance report and the Brazilian national ART programme. RESULTS: Models were calibrated using 921,157 adult and 37,431 paediatric viral load measurements, over 2010-2019. The Pareto and reverse Weibull models provided the best fits to the data, but for all models, the "shape" parameters for the viral load distributions differed significantly between regions. The Weibull model performed best in the validation against the WHO drug resistance survey data, while the Pareto model produced uncertainty ranges that were too narrow, relative to the validation data. Based on these analyses, we recommend using the reverse Weibull model. For example, if a country reports an 80% rate of viral suppression at <200 copies/ml, this model estimates the proportion virally suppressed at <1000 copies/ml is 88.3% (0.80(0.56) ), with uncertainty range 85.5-90.6% (0.80(0.70) -0.80(0.44) ). CONCLUSIONS: Estimates of viral ...
العلاقة: 1758-2652 (Electronic) 1758-2652 (Linking); https://oskar-bordeaux.fr/handle/20.500.12278/123942Test
الإتاحة: https://doi.org/20.500.12278/123942Test
https://doi.org/10.1002/jia2.25776Test
https://oskar-bordeaux.fr/handle/20.500.12278/123942Test
https://hdl.handle.net/20.500.12278/123942Test -
3دورية أكاديمية
المؤلفون: Jaquet, Antoine, Ekouevi, Didier-Koumavi, Aboubakrine, Maiga, Bashi, Jules, Messou, Eugène, Maiga, Moussa, Traore, Hamar-Alassane, Zannou, Marcel, Guehi, Calixte, Ba-Gomis, Franck-Olivier, Minga, Albert, K., Allou, Gérard, Eholie, Serge-Paul, Dabis, Francois, Bissagnene, Emmanuel, Sasco, Annie-Jeanne
المساهمون: Epidémiologie et Biostatistique Bordeaux, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Programme PAC-CI, ANRS France Recherche Nord & sud Sida-hiv hépatites, Service d'Hépato-Gastro-Entérologie, Hôpital Gabriel Touré Mali, Centre de Prise en Charge des Personnes vivant avec le VIH, CHNU, Centre de Prise en Charge de Recherches et de Formation, Centre de Prise en charge, de Recherche et de Formation (CePReF), Centre Hospitalier Universitaire du PointG Bamako, Unité de Soins Ambulatoires et de Conseils (USAC), Centre Intégré de Recherche Bioclinique d'Abidjan, CENTRE INTÉGRÉ DE RECHERCHES BIOCLINIQUES D'ABIDJAN (CIRBA) (CIRBA), Centre Médical de Suivi de Donneurs de Sang, CNTS/PRIMO-CI, Service de Maladies Infectieuses et Tropicales (SMIT), Hôpital de Treichville
المصدر: ISSN: 1027-3719.
مصطلحات موضوعية: [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
الوصف: International audience ; BACKGROUND: Tobacco smoking is common in human immunodeficiency virus (HIV) infected patients from industrialised countries. In West Africa, few data concerning tobacco consumption exist. METHODS: A cross-sectional survey of the International Epidemiological Database to Evaluate AIDS (IeDEA) network in West Africa was conducted. Health workers administered a questionnaire assessing tobacco and cannabis consumption among patients receiving antiretroviral treatment. Regular smokers were defined as current smokers who smoked >1 cigarette per day for >or=1 year. RESULTS: Overall, 2920 patients were enrolled in three countries. The prevalence of ever smokers and regular smokers were respectively 46.2% (95%CI 42.8-49.5) and 15.6% (95%CI 13.2-18.0) in men and 3.7% (95%CI 2.9-4.5) and 0.6% (95%CI 0.3-0.9) in women. Regular smoking was associated with being from Côte d'Ivoire or Mali compared to Benin (OR 4.6, 95%CI 2.9-7.3 and 7.7, 95%CI 4.4-13.6), severely impaired immunological status at highly active antiretroviral treatment initiation (OR 1.5, 95%CI 1.1-2.2) and history of tuberculosis (TB; OR 1.8, 95%CI 1.1-3.0). CONCLUSION: There are marked differences in smoking prevalence among these West African countries. This survey approach also provides proof of the association between cigarette smoking and TB in HIV-infected patients, a major public health issue in this part of the world.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/19861019; inserm-00399020; https://inserm.hal.science/inserm-00399020Test; https://inserm.hal.science/inserm-00399020/documentTest; https://inserm.hal.science/inserm-00399020/file/inserm-00399020_edited.pdfTest; https://inserm.hal.science/inserm-00399020/file/Jaquet_manuscript_IJTLD-04-09-0196.R1.pdfTest; PUBMED: 19861019
-
4دورية أكاديميةDo tests devised to detect recent HIV-1 infection provide reliable estimates of incidence in Africa?
المؤلفون: Sakarovitch, Charlotte, Rouet, Francois, Murphy, Gary, Minga, Albert, K., Alioum, Ahmadou, Dabis, Francois, Costagliola, Dominique, Salamon, Roger, Parry, John, V., Barin, Francis
المساهمون: Equipe de Biostatistique, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR99-ISPED, Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche et de Diagnostic sur le Sida Abidjan, Côte d'Ivoire (CeDreS), Centre Hospitalier Universitaire de Treichville Abidjan, Côte d'Ivoire (CHU de Treichville), Virus Reference Department, Health Protection Agency Centre for Infections London, PRIMO-CI, Programme PAC-CI (ANRS 1220), ANRS France Recherche Nord & sud Sida-hiv hépatites, Epidémiologie Clinique et Traitement de l'Infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-IFR113-Institut National de la Santé et de la Recherche Médicale (INSERM), Virus, pseudo-virus: Morphogénèse et Antigénicité, Université de Tours (UT)-EA3856
المصدر: ISSN: 1525-4135.
مصطلحات موضوعية: MESH: AIDS Serodiagnosis, MESH: Africa, MESH: Incidence, MESH: Population Surveillance, MESH: Prevalence, MESH: ROC Curve, MESH: Reproducibility of Results, MESH: Sensitivity and Specificity, MESH: Time Factors, MESH: Biological Assay, MESH: Cohort Studies, MESH: HIV Infections, MESH: HIV Seropositivity, MESH: HIV Seroprevalence, MESH: HIV-1, MESH: Humans, MESH: Immunoenzyme Techniques, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
الوصف: International audience ; The objective of this study was to assess the performance of 4 biologic tests designed to detect recent HIV-1 infections in estimating incidence in West Africa (BED, Vironostika, Avidity, and IDE-V3). These tests were assessed on a panel of 135 samples from 79 HIV-1-positive regular blood donors from Abidjan, C?d'Ivoire, whose date of seroconversion was known (Agence Nationale de Recherches sur le SIDA et les H?tites Virales 1220 cohort). The 135 samples included 26 from recently infected patients (< or =180 days), 94 from AIDS-free subjects with long-standing infection (>180 days), and 15 from patients with clinical AIDS. The performance of each assay in estimating HIV incidence was assessed through simulations. The modified commercial assays gave the best results for sensitivity (100% for both), and the IDE-V3 technique gave the best result for specificity (96.3%). In a context like Abidjan, with a 10% HIV-1 prevalence associated with a 1% annual incidence, the estimated test-specific annual incidence rates would be 1.2% (IDE-V3), 5.5% (Vironostika), 6.2% (BED), and 11.2% (Avidity). Most of the specimens falsely classified as incident cases were from patients infected for >180 days but <1 year. The authors conclude that none of the 4 methods could currently be used to estimate HIV-1 incidence routinely in C?d'Ivoire but that further adaptations might enhance their accuracy.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/17460475; inserm-00175885; https://inserm.hal.science/inserm-00175885Test; https://inserm.hal.science/inserm-00175885/documentTest; https://inserm.hal.science/inserm-00175885/file/Sakarovitch_JAIDS2007.pdfTest; PUBMED: 17460475
الإتاحة: https://doi.org/10.1097/QAI.0b013e318050d277Test
https://inserm.hal.science/inserm-00175885Test
https://inserm.hal.science/inserm-00175885/documentTest
https://inserm.hal.science/inserm-00175885/file/Sakarovitch_JAIDS2007.pdfTest -
5دورية أكاديمية
المؤلفون: Danel, Christine, Moh, Raoul, Peytavin, Gilles, Anzian, Amani, Minga, Albert, K., Gomis, Olivier Ba, Seri, Boga, Nzunettu, Gustave, Gabillard, Delphine, Salamon, Roger, Bissagnene, Emmanuel, Anglaret, Xavier
المساهمون: Programme PAC-CI, ANRS France Recherche Nord & sud Sida-hiv hépatites, Service de Pharmacologie Clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Epidémiologie, santé publique et développement, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville
المصدر: ISSN: 0889-2229.
مصطلحات موضوعية: MESH: Cohort Studies, MESH: Indinavir, MESH: Male, MESH: RNA, Viral, MESH: Retrospective Studies, MESH: Time Factors, MESH: Treatment Outcome, MESH: Viral Load, MESH: Adult, MESH: Cote d'Ivoire, MESH: Female, MESH: Follow-Up Studies, MESH: HIV Infections, MESH: HIV Protease Inhibitors, MESH: HIV-1, MESH: HIV-2, MESH: Humans, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases
الوصف: International audience ; To report the tolerance of indinavir combined with ritonavir (IDV/r 800/100 mg) twice daily (bid) in sub-Saharan African HIV-infected adults. HAART-naives patients started zidovudine plus lamivudine plus IDV/r 800/100 mg bid. Follow-up included standardized documentation of morbidity, CD4(+) cell count, creatininemia, plasma HIV-1 RNA, and IDV minimal plasma concentration (C(min)) measurements at month 1 (M1), M3, and M6. Seventy HIV-1-infected adults (68 women, median CD4 235/mm(3)) started HAART. At M6, 63% had undetectable viral load, and the median gain in CD4 since baseline was +128/mm(3). During the first 6 months, 21 patients experimented with 23 treatment modifications (reduction in IDV/r 400/100 mg bid, n = 11; switch to efavirenz, n = 11; zidovudine replaced by stavudine, n = 1), including 22 for digestive intolerance and 1 for severe anemia. At M1, M3, and M6, 67, 59, and 48 patients were still receiving IDV/r 800/100 mg bid, of whom 70%, 72%, and 60% had IDV Cmin above 5 ng/ml, respectively. In these patients, at M1, M3, and M6, the mean (+/- SD) IDV C(min) were 3431 +/- 3835 ng/ml, 2288 +/- 2116 ng/ml, and 1543 +/- 2398 ng/ml, respectively. There was no renal insufficiency of any grade, and no symptoms of urinary stones. The IDV/r 800/100 mg bid-containing regimen led to high IDV Cmin and a high rate of digestive intolerance. There was a surprising lack of nephrological side effects during the 6 months of follow-up, supporting the hypothesis that nephrological tolerance of IDV might be higher in sub-Saharan African individuals than in Americans or Europeans.
العلاقة: info:eu-repo/semantics/altIdentifier/pmid/17263634; inserm-00173523; https://inserm.hal.science/inserm-00173523Test; https://inserm.hal.science/inserm-00173523/documentTest; https://inserm.hal.science/inserm-00173523/file/inserm-00173523_edited.pdfTest; https://inserm.hal.science/inserm-00173523/file/Danel_Indinavir_nephrological_complications_in_Africa_AIDS_Res_Hum_Retrovir_2007_in_press.pdfTest; PUBMED: 17263634
الإتاحة: https://doi.org/10.1089/aid.2006.0038Test
https://inserm.hal.science/inserm-00173523Test
https://inserm.hal.science/inserm-00173523/documentTest
https://inserm.hal.science/inserm-00173523/file/inserm-00173523_edited.pdfTest
https://inserm.hal.science/inserm-00173523/file/Danel_Indinavir_nephrological_complications_in_Africa_AIDS_Res_Hum_Retrovir_2007_in_press.pdfTest -
6
المؤلفون: Tsiara, Chrissa G., Nikolopoulos, Georgios K., Bagos, Pantelis G., Goujard, Cecile, Katzenstein, Terese L., Minga, Albert K., Rouzioux, C., Hatzakis, A.
المساهمون: Nikolopoulos, Georgios K.[0000-0002-3307-0246], Bagos, Pantelis G. [0000-0003-4935-2325]
المصدر: AIDS Research and Human Retroviruses
مصطلحات موضوعية: Male, Oncology, Human immunodeficiency virus 1, Disease, Bioinformatics, Viral load, Viral, Disease course, Priority journal, Biological markers, Predictive marker, Virus rna, Medline, Viral Load, Prognosis, Comparative effectiveness, Death, Acquired immunodeficiency syndrome, Infectious Diseases, Acquired immune deficiency syndrome, Virus dna, Meta-analysis, Predictive value of tests, Disease Progression, RNA, Viral, Female, Human, medicine.medical_specialty, Immunology, Predictive value, Bivariate analysis, Article, Acquired immunodeficiency syndrome (AIDS), Predictive Value of Tests, Virology, Internal medicine, medicine, Humans, Acquired Immunodeficiency Syndrome, Disease progression, Intermethod comparison, business.industry, Hiv-1, Dna, medicine.disease, Confidence interval, Relative risk, DNA, Viral, HIV-1, Rna, business, Biomarkers, Meta analysis
الوصف: Several studies have reported the prognostic strength of HIV-1 DNA with variable results however. The aims of the current study were to estimate more accurately the ability of HIV-1 DNA to predict progression of HIV-1 disease toward acquired immunodeficiency syndrome (AIDS) or death, and to compare the prognostic information obtained by HIV-1 DNA with that derived from plasma HIV-1 RNA. Eligible articles were identified through a comprehensive search of Medline, ISI Web of Science, Scopus, and Google Scholar. The analysis included univariate and bivariate random-effects models. The univariate meta-analysis of six studies involving 1074 participants showed that HIV-1 DNA was a strong predictive marker of AIDS [relative risk (RR): 3.01, 95% confidence interval (CI): 1.88-4.82] and of all-cause mortality (RR: 3.49, 95% CI: 2.06-5.89). The bivariate model using the crude estimates of primary studies indicated that HIV-1 DNA was a significantly better predictor than HIV-1 RNA of either AIDS alone (ratio of RRs=1.47, 95% CI: 1.05-2.07) or of combined (AIDS or death) progression outcomes (ratio of RRs=1.51, 95% CI: 1.11-2.05). HIV-1 DNA is a strong predictor of HIV-1 disease progression. Moreover, there is some evidence that HIV-1 DNA might have better predictive value than plasma HIV-1 RNA. © 2012, Mary Ann Liebert, Inc. 28 4 366 373
الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26f502fdb3cdf88788acd38eea1d43a3Test
https://doi.org/10.1089/aid.2011.0032Test -
7دورية أكاديمية
المؤلفون: Minga, Albert K, Lewden, Charlotte, Gabillard, Delphine, Bomisso, Germain I, Toni, Thomas-d'Aquin, Emième, Arlette A, Yapo, Vincent, Inwoley, André, Salamon, Roger, Anglaret, Xavier
المصدر: AIDS ; volume 25, issue 6, page 819-823 ; ISSN 0269-9370
الإتاحة: https://doi.org/10.1097/qad.0b013e32834625d3Test
http://journals.lww.com/00002030-201103270-00012Test -
8كتاب
المصدر: Modeling NMR Chemical Shifts ; ACS Symposium Series ; page 207-219 ; ISSN 0097-6156 1947-5918 ; ISBN 9780841236226 9780841217256
-
9دورية أكاديمية
المؤلفون: Tiendrebeogo, Thierry, Malateste, Karen, Poda, Armel, Minga, Albert K., Messou, Eugène, Chenal, Henri, Mensah, Ephrem, Ezechi, Oliver, Ekouevi, Didier K., Ofotokun, Igho, Jaquet, Antoine
المصدر: Topics in Antiviral Medicine; Apr2023, Vol. 31 Issue 2, p424-424, 1/2p
-
10دورية أكاديمية
المؤلفون: Tiendrebeogo, Thierry, Malateste, Karen, Poda, Armel, Minga, Albert K., Lahiri, Cecile D., Ezechi, Oliver, Ekouevi, Didier K., Ofotokun, Igho, Jaquet, Antoine
المصدر: Topics in Antiviral Medicine; Apr2023, Vol. 31 Issue 2, p279-279, 1/2p
